A prospective study on bacterial and atypical etiology of acute exacerbation in chronic obstructive pulmonary disease

Future Microbiology

Volumn 9, Issue 11, 2014, Pages 1251-1260

  Nakou, Alexandra ^a,b   Papaparaskevas, Joseph ^a   Diamantea, Filia ^b   Skarmoutsou, Nikoletta ^b   Polychronopoulos, Vlasis ^b   Tsakris, Athanassios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

Author keywords

Chlamydia pneumoniae; culture; exacerbation of COPD; Mycoplasma pneumoniae; PCR; sputum

Indexed keywords

ACINETOBACTER BAUMANNII; AGED; AIRWAY OBSTRUCTION; ARTICLE; BACTERIUM DETECTION; CHLAMYDIAL PNEUMONIA; CHLAMYDOPHILA PNEUMONIAE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CITROBACTER FREUNDII; CORYNEBACTERIUM STRIATUM; DELFTIA ACIDOVORANS; DIAGNOSTIC PROCEDURE; DISEASE DURATION; DISEASE EXACERBATION; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; FEMALE; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; HOSPITAL PATIENT; HUMAN; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORAXELLA CATARRHALIS; MORGANELLA MORGANII; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; SMOKING; SPUTUM CULTURE; STREPTOCOCCUS PNEUMONIAE; BACTERIUM IDENTIFICATION; GENETICS; HOSPITALIZATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT INFECTION; SPUTUM; VERY ELDERLY;

BACTERIA (MICROORGANISMS); CHLAMYDOPHILA PNEUMONIAE; MYCOPLASMA PNEUMONIAE;

BACTERIAL DNA;

ACINETOBACTER BAUMANNII; AGED; AGED, 80 AND OVER; BACTERIAL TYPING TECHNIQUES; CHLAMYDOPHILA PNEUMONIAE; DNA, BACTERIAL; FEMALE; HAEMOPHILUS INFLUENZAE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MYCOPLASMA PNEUMONIAE; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT INFECTIONS; SPUTUM;

EID: 84914671685     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.14.90     Document Type: Article

References (40)

1. Perera WR, Hurst JR, Wilkinson TM et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur. Respir. J. 29, 527-534 (2007).
2. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2014). www.goldcopd.org/
3. World Health Organization. The world health report 2006: working together for health. www.who.int/whr/2006/whr06-en.pdf
4. Anthonisen NR, Connett JE, Kiley JP et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 272, 1497-1505 (1994)
5. Vestbo J, Sørensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease. Lancet 353, 1819-1823 (1999).
6. Burge PS, Calverley PM, Jones PW, Spencer K, Anderson JA, Maslen TK. Randomized, double blind placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320, 1297-1303 (2000).
7. Burrows B, Knudson RJ, Cline MG, Lebowitz MD. Quantitative relationships between cigarette smoking and ventilatory function. Am. Rev. Respir. Dis. 115, 195-205 (1977).
8. Trupin L, Earnest G, San Pedro M et al. The occupational burden of chronic obstructive pulmonary disease. Eur. Respir. J. 22, 462-469 (2003).
9. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J. Respir. Crit. Care Med. 157, 1418-1422 (1998).
10. Donaldson GC, Wilkinson TM, Hurst JR, Perera WR, Wedzicha JA. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 171, 446-452 (2005).
11. Patel IS, Seemungal TA, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 57, 759-764 (2002).
12. Donaldson GC, Seemungal TA, Patel IS et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 128, 1995-2004 (2005).
13. White AJ, Gompertz S, Stockley RA. Chronic obstructive pulmonary disease. 6: the aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax 58, 73-80 (2003).
14. Dowell SF, Peeling RW, Boman J et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin. Infect. Dis. 33, 492-503 (2001).
15. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N. Engl. J. Med. 359, 2355-2365 (2008).
16. Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin. Microbiol. Rev. 14, 336-363 (2001).
17. Wedzicha JA. Role of viruses in exacerbations of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 1, 115-120 (2004).
18. Blasi F, Damato S, Cosentini R et al. Chlamydia pneumoniae and chronic bronchitis: association with severity and bacterial clearance following treatment. Thorax 57, 672-676 (2002).
19. Blasi F, Consentini R, Tarsia P. Chlamydia pneumoniae respiratory infections. Curr. Opin. Infect. Dis. 13, 161-164 (2000).
20. Miravitlles M, Espinosa C, Fernades-Laso E, Martos JA, Maldonado JA, Gallego M. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 116, 40-46 (1999).
21. Lieberman D, Lieberman D, Ben-Yaakov M et al. Serological evidence of Mycoplasma pneumoniae infection in acute exacerbation of COPD. Diagn. Microbiol. Infect. Dis. 44, 1-6 (2002).
22. Mogulkoc N, Karakurt S, Isalska B et al. Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection. Am. J. Respir. Crit. Care Med. 160, 349-353 (1999).
23. Diederen B, van der Valk P, Kluytmans, Peeters M, Hendrix R. The role of atypical respiratory pathogens in exacerbations of chronic obstructive pulmonary disease. Eur. Respir. J. 30, 240-244 (2007).
24. Monsó E, Ruiz J, Rosell A et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated patients using the protective specimen brush. Am. J. Respir. Crit. Care Med. 152, 1316-1320 (1995).
25. Soler N, Torres A, Ewig S et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease requiring mechanical ventilation. Am. J. Respir. Crit. Care Med. 157, 1498-1505 (1998).
26. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57, 847-852 (2002).
27. Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Lode H. Infective exacerbations of chronic bronchitis. Relation between bacteriologic etiology and lung function. Chest 113, 1542-1548 (1998).
28. Varma-Basil M, Dwivedi SK, Kumar K et al. Role of Mycoplasma pneumoniae infection in acute exacerbations of chronic obstructive pulmonary disease. J. Med. Microbiol. 58, 322-326 (2009).
29. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Disk Susceptibility Testing; Approved Standard-Ninth Edition. M02-A9. Clinical and Laboratory Standards Institute, PA, USA (2006).
30. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement. M100s18. Clinical and Laboratory Standards Institute, PA, USA (2008).
31. Tong CY, Donnelly C, Harvey G, Sillis M. Multiplex polymerase chain reaction for the simultaneous detection of Mycoplasma pneumoniae, Chlamydia pneumoniae and Chlamydia psittaci in respiratory samples. J. Clin. Pathol. 52, 257-263 (1999).
32. Jonas D, Rosenbaum A, Weyrich S, Bhakdi S. Enzyme-linked immunoassay for detection of PCR-amplified DNA of Legionellae in bronchoalveolar fluid. J. Clin. Microbiol. 33, 1247-1252 (1995).
33. Tuuminen T, Varjo S, Ingman H, Weber T, Oksi J, Viljanen M. Prevalence of Chlamydia pneumoniae and Mycoplasma pneumoniae immunoglobulin G and A antibodies in a healthy Finnish population as analyzed by quantitative enzyme immunoassays. Clin. Diagn. Lab. Immunol. 7, 734-738 (2000).
34. Kumar S, Hammerschlag MR. Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods. Clin. Infect. Dis. 44, 568-576 (2007).
35. Blasi F, Legnani D, Lombardo VM et al. Chlamydia pneumoniae infection in acute exacerbations of COPD. Eur. Respir. J. 6, 19-22 (1993).
36. Von Hertzen L, Isoaho R, Leinonen M et al. Chlamydia pneumoniae antibodies in chronic obstructive pulmonary disease. Int. J. Epidemiol. 25, 658-664 (1996).
37. Lieberman D, Lieberman D, Shmarkov O et al. Serological evidence of Legionella species infection in acute exacerbation of COPD. Eur. Respir. J. 19, 392-397 (2002).
38. Van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C, Hendrix R. Clinical predictors of bacterial involvement in exacerbations of chronic obstructive pulmonary disease. Clin. Infect. Dis. 39, 980-986 (2004).
39. Gan WQ, Paul Man SF, Sin DD. The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest 127, 558-564 (2005).
40. Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Lode H. Infective exacerbations of chronic bronchitis. Relation between bacteriologic etiology and lung function. Chest 113, 1542-1548 (1998).